Streetbeat News

Analyst Ratings

SNA

Snap-on (NYSE:SNA) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target is $318.33, slightly down from the previous $319.50. Snap-on's financials show strong net margins and ROE, but revenue growth has faced challenges.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 6:00 pm

RARE

Ultragenyx Pharmaceutical (NASDAQ:RARE) received mixed analyst ratings, with a majority being somewhat bullish. Analysts set a 12-month average price target of $89.7, slightly up from the previous $88.30. The company's financials show strong revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 6:00 pm

CRBP

B. Riley Securities has maintained a Buy rating on Corbus Pharmaceuticals but has lowered the price target from $85 to $40.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:59 pm

SKYE

Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:57 pm

CHWY

Piper Sandler analyst Peter Keith has reiterated an Overweight rating on Chewy (NYSE:CHWY) and maintained a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:54 pm

NKE

Piper Sandler analyst Anna Andreeva has reiterated a Neutral rating on Nike (NYSE:NKE) and maintained a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:52 pm

CVX

Chevron has seen unusual options activity with a bearish sentiment, as 62% of trades were bearish. The options activity suggests a targeted price range of $80 to $155. Despite this, analysts maintain a positive outlook with a price target of $189.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 5:47 pm

RBLX

Roblox (NYSE:RBLX) has seen a surge in options activity with equal bullish and bearish trades. The focus is on a price range of $40-$50. Current trading volume is high, but the stock is down 1.25% at $45.72. Analysts have set a price target of $51, with BTIG maintaining a Buy rating.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 5:47 pm

PPBT

HC Wainwright & Co. has maintained a Buy rating on Purple Biotech (NASDAQ:PPBT) and adjusted its price target to $33 following a 1-20 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:38 pm

DRI

Wells Fargo analyst Zachary Fadem maintains an Equal-Weight rating on Darden Restaurants and raises the price target from $160 to $165.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:38 pm